The implant is designed to fill cartilage lesions with acellular material so cartilage will regenerate in the knee in the exact shape as the defect, according to the news release. For any traumatic knee injuries, GelrinC can be inserted as a liquid and converted to a solid through ultra violet light to ultimately relieve patient joint pain.
Regentis is currently conducting clinical trials in Europe with its investigational version of GelrinC.
More Articles on Devices:
Zimmer Looking to Grow Emerging Orthopedic Markets
Stryker Launches Spinal Pedicle Screw
500 Invibio PEEK-OPTIMA Devices Cleared for US Use
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.